Whole-body FDG-PET in patients with stage I non-seminomatous germ cell tumours

Lassen, Ulrik; Daugaard, Gedske; Eigtved, Annika; Højgaard, Liselotte; Damgaard, Karen; Rørth, Mikael

doi:10.1007/s00259-002-1075-z

Cited by 105 publications

(34 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…FDG PET appears to be superior to conventional imaging for restaging for testicular cancer, by depicting it sooner and being more sensitive for small lesions (189)(190)(191). The specificity and sensitivity, respectively, of FDG PET were 100% and 80% versus 74% and 70% for CT in an investigation of residual tumor after chemotherapy (192).…”

Section: Testicular Cancermentioning

confidence: 95%

Molecular Imaging Techniques in Body Imaging

et al. 2007

View full text Add to dashboard Cite

Molecular imaging of the body involves new techniques to image cellular biochemical processes, which results in studies with high sensitivity, specificity, and signal-to-background. The most prevalently used molecular imaging technique in body imaging is currently fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (PET). FDG PET has become the method of choice for the staging and restaging of many of the most common cancers, including lymphoma, lung cancer, breast cancer, and colorectal cancer. FDG PET has also become extremely valuable in monitoring the response to therapeutic drugs in many cancers. New PET agents, such as fluorothymidine and acetate, have also shown promise in the evaluation of response to therapy and in the staging of prostate cancer. Magnetic resonance (MR) spectroscopy has shown promise in the evaluation of prostate cancer. Breast cancer evaluation benefits from advances in spectroscopic imaging and contrast-enhanced kinetic evaluation of vascular permeability, which is altered in neoplastic processes because of release of angiogenic factors. Superparamagnetic iron oxide (SPIO) particles represent the first of an expanding line of MR contrast agents that target specific cellular processes. SPIO particles have also been used in the evaluation of the cirrhotic liver and at MR lymphangiography.

show abstract

Section: Testicular Cancermentioning

confidence: 95%

Molecular Imaging Techniques in Body Imaging

et al. 2007

View full text Add to dashboard Cite

show abstract

“…Many authors have evaluated the role of FDG-PET for initial staging and produced variable results. [133][134][135][136] Tsatalpas et al compare PET and CT in 32 patients with testicular cancer. [134] Though not statistically significant, FDG-PET was found superior to CT scan in detecting metastatic infradiaphragmatic and supradiaphragmatic lesions.…”

Section: Testicular Cancermentioning

confidence: 98%

Clinical applications of positron emission tomography-computed tomography in oncology

2010

View full text Add to dashboard Cite

Positron emission computed tomography (PET) is a functional diagnostic imaging technique, which can accurately measure in vivo distribution of a variety of radiopharmaceuticals. The ability of PET to study various biological processes (glucose, amino acid, phospholipids, receptors etc.) opens up new possibilities for both day-to-day clinical use and research applications in the practice of oncology. Addition of CT to PET has resulted in better specificity and sensitivity than either of the modalities alone, as the combined approach has the ability to demonstrate functional and structural details in the same setting. F-18 fluoro-2-deoxy-D-glucose (FDG), an analogue of glucose, is the most commonly used radiotracer in PET-CT imaging. The F-18 FDG uptake in tumor cells is directly proportional to glucose metabolism in the cells. Since glucose metabolism is increased several folds in the malignant tumors, PET-CT images show preferential higher FDG uptake in malignant cells as compared to normal cells. F-18 FDG PET-CT has been found to be useful in the initial staging, detection of recurrent disease and monitoring the response to the therapy in malignancies including lung cancer, colorectal cancer, lymphoma, melanoma, esophageal cancer, head and neck cancer, breast cancer.

show abstract

“…The clinical staging error remains an issue of concern although the false-negative staging error may be minimized by the evaluation of CT scans by doctors with expertise in specialized centers [29]. Positron emission tomography (PET) may improve the imaging results, but this approach is more important for clinical stage II disease [39,40]. Recently, Huddart et al [41] conducted a trial in high-risk patients in order to examine whether a PET scan could identify patients without occult metastatic disease for whom surveillance is an attractive option.…”

Section: Surveillancementioning

confidence: 99%